Results 141 to 150 of about 67,015 (304)

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats:The REVEAL Study [PDF]

, 2018
Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved.
Abbott, Jonathan A, Amberger, Christophe, Borgarelli, Michele, Bossbaly, Maribeth J, Bové, Christina M, Brambilla, Paola, Bright, Janice M, Bulmer, Barret, Bussadori, Claudio, Chetboul, Valerie, Culshaw, Geoffrey, Côté, Etienne, De Swarte, Marie, Estrada, Amara H, Fernández-Del Palacio, Maria Josefa, Fine-Ferreira, Deborah M, Fox, Philip R, Fujii, Yoko, Gordon, Sonya G, Hogan, Daniel F, Hung, Yong-Wei, Häggström, Jens, Jung, Seung Woo, Keene, Bruce W, Komolov, Andrey, Lamb, Kenneth, Lee, Pamela M, Lesser, Michael B, Lobetti, Remo, Luis Fuentes, Virginia, Lunney Brayley, Jenifer, Manczur, Ferenc, Mooney, Carmel T, Motsinger-Reif, Alison, Moïse, N Sydney, Nakamura, Reid K, Ohad, Dan G, Oyama, Mark A, Pariaut, Romain, Payne, Jessie Rose, Quick, Nadine, Quintavalla, Cecilia, Riesen, Sabine, Rush, John E, Santilli, Roberto A, Schober, Karsten A, Schwartz, Denise S, Singh, Manreet K, Stauthammer, Christopher D, Stepien, Rebecca L, Tachika Ohara, Victoria Yukie, Tamborini, Alice, Trehiou-Sechi, Emilie, Uechi, Masami, Van Israël, Nicole, Vollmar, Andrea C, Ware, Wendy A, Wess, Gerhard   +57 more
core   +5 more sources

Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation

Advanced Science, Volume 13, Issue 7, 3 February 2026.
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu, Yawei Shen, Robert J. Barndt, Karim Sallam, Ying Tang, Cameron E. Brown, Xiao Li, Stephen Y. Chan, Joseph C. Wu, Qing Liu, Haodi Wu   +10 more
wiley   +1 more source

Hypertrophic cardiomyopathy: Part 1 - Introduction, pathology and pathophysiology

Annals of Cardiac Anaesthesia, 2014
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with many genotype and phenotype variations. Earlier terminologies, hypertrophic obstructive cardiomyopathy and idiopathic hypertrophic sub-aortic stenosis are no longer ...
Praveen Kerala Varma, Praveen Kumar Neema   +1 more
doaj   +1 more source

Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement [PDF]

, 2016
AIMS: Prevalence and clinical significance of right atrial enlargement (RAE) has been poorly characterized in hypertrophic cardiomyopathy. METHODS: One hundred and sixty consecutive patients with hypertrophic cardiomyopathy (35.5 ± 20 years; 64% men ...
Bossone, E, Calabro, R, Elliott, P, Ferrara, I, Frisso, G, Gravino, R, Iacomino, M, Limongelli, G, Masarone, D, Pacileo, G, Rea, A, Salvatore, F   +11 more
core  

Survival After Myectomy for Obstructive Hypertrophic Cardiomyopathy: What Causes Late Mortality? [PDF]

, 2019
Anita Nguyen, Hartzell V. Schaff, Rick A. Nishimura, Jeffrey B. Geske, Michael J. Ackerman, J. Martijn Bos, Joseph A. Dearani, Steve R. Ommen   +7 more
openalex   +1 more source

The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

American Journal of Medical Genetics Part A, Volume 200, Issue 2, Page 407-418, February 2026.
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen, Eveliina Brandt, Kaisa Kettunen, Outi Elomaa, Sirpa Kivirikko, Leila Jeskanen, Katriina Lappalainen, Nelli Sjöblom, Juha Kere, Katariina Hannula‐Jouppi, Liisa Harjama   +10 more
wiley   +1 more source

Hypertrophic obstructive cardiomyopathy [PDF]

The Journal of Thoracic and Cardiovascular Surgery, 1997
Morton E. Tavel, Lameh Fananapazir, Nora F. Goldschlager   +2 more
openaire   +2 more sources

A Long-Term Prognosis of Adaptive Servo Ventilation Therapy for Patients with Heart Failure -Consideration in Severity of Sleep-Disordered Breathing- [PDF]

, 2019
学位記番号 ...
Goto, Keita, ゴトウ, ケイタ, 後藤, 慶大   +2 more
core   +1 more source

Proceedings: Recognition of hypertrophic obstructive cardiomyopathy in childhood. [PDF]

, 1975
G I Fiddler, M J Godman
openalex   +1 more source